

Hemophilia Treatment Market is expected to reach US\$ 44,089.71 million in 2027

Pune, Apr 15, 2020 (IssueWire.com) - According to The Insight Partners market research study titled 'Hemophilia Treatment Market - Global Analysis and Forecasts by Product, Disease, Treatment Type, Therapy, and End User, the global hemophilia treatment market is expected to reach US\$ 44,089.71 Mn in 2027 from US\$ 14,454.81 Mn in 2019. The market is estimated to grow with a CAGR of 15.9% from 2020-2027. The report highlights the trends prevalent in the global hemophilia treatment market and the factors driving the market along with those that act as deterrents to its growth.

The [hemophilia treatment market](#) by product is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma-derived coagulation factor concentrates segment held the largest market share of the hemophilia treatment market. This segment is also expected to dominate the market in 2027. The large share of plasma-derived coagulation factor concentrates based hemophilia treatment can be attributed to various advantages offered by this hemophilia treatment, deep market penetration and variety of products offered by multiple players to suit the diverse medical application. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest growth rate during the forecast period. Certain factors such as the effectiveness of the hemophilia treatment in lesser time and better efficient blood clotting are expected to drive the segment growth.

Factors such as an increase in the number of surgical procedures and increasing incidences of sports injuries are expected to upsurge the market growth. In addition, growth in the global healthcare market is likely to have a positive impact on the growth of the market in the coming years.

Some of the prominent players operating in hemophilia treatment market are, Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, and Baxter International Inc. The market players are focused towards acquisitions with industry players in order to sustain their position in the market. For instance, in February 2020, Novo Nordisk launched an antihemophilic product namely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.

The report segments the global hemophilia treatment market as follows:

Global Hemophilia Treatment Market – By Product

- Plasma Derived Coagulation Factor Concentrates
 - Factor VIII Market
 - Factor IX Market
 - Factor XIII Market
 - Activated Prothrombin Complex Concentrate Market
- Recombinant Coagulation Factor Concentrates
- Desmopressin
- Antifibrinolytic Agents

Global Hemophilia Treatment Market – By Disease

- Hemophilia A

- Hemophilia B
- Hemophilia C

Global Hemophilia Treatment Market – By Treatment Type

- On-demand
- Prophylaxis

Global Hemophilia Treatment Market – By Therapy

- Replacement Therapy
- ITI Therapy
- Gene Therapy
- Antibody Therapy

Global Hemophilia Treatment Market – By End User

- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others

Media Contact

theinsightpartners

jitendra.more@theinsightpartners.com

02067271632

533, 5th Floor,, Amanora Chambers, East Block, Amanora Township,, Kharadi Road, Hadapsar,
Pune-411028

Source : theinsightpartners

[See on IssueWire](#)